Ziftomenib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, with potential antineoplastic activity. Upon oral administration, ziftomenib prevents the interaction between the two proteins menin and MLL, and thus the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth and proliferation of certain kinds of leukemia cells.

**Synonyms:** - KO 539 - KO-539 - KO539 - Komzifti - Menin-KMT2A Inhibitor KO 539 - Menin-MLL Inhibitor KO-539 - Menin-MLL Interaction Inhibitor KO 539 - Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor KO 539 - ZIFTOMENIB